Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China

Monday, September 30, 2019

Eisai Co Ltd and NichiIko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China The Chinese pharmaceutical market is the second largest market in the world after the United States an...

Sysmex Inostics Launches Two NGS-based Liquid Biopsy Panels for Cancer Therapy Drug Development

Monday, September 30, 2019

Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA ctDNA analysis SafeSEQ is a nextgeneration sequencing NGSbased a...

Ensysce Biosciences Receives Multi-Year NIH HEAL Grant to Develop a Novel Opioid-Use-Disorder (OUD) Medication

Friday, September 27, 2019

Ensysce Biosciences Inc a clinical stage company today announced receipt of Notice of Award from the National Institute on Drug Abuse NIDA for a million five year award to undertake the preclinical and clinical development of the companys opioidused...

Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-opiate Treatment of Chronic Pain

Friday, September 27, 2019

Knopp Biosciences LLC announced today that the National Institutes of Health NIH has awarded a grant of up to million to use its new Kv platform for research and development Innovative nonopioid therapies for the treatment of chronic pain This mult...

TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer

Thursday, September 26, 2019

Tyme Technologies Inc an emerging biotechnology company developing cancer metabolismbased therapies CMBTs today announced the start of the pivotal stage of the TYMEPanc trial to evaluate the clinical benefits of its lead CMBT candidate oral SM raceme...

Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

Thursday, September 26, 2019

Achillion Pharmaceuticals Inc a clinicalstage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complementmediated diseases today announced that the US Food and Drug Administration FDA has granted Brea...

NST Doses First Patient in Phase 2b Clinical Study of Icosabutate in NASH (‘ICONA’)

Wednesday, September 25, 2019

NorthSea Therapeutics BV NST a Dutch biotech company developing novel and innovative strategies for the treatment of NASH Nonalcoholic Steatohepatitis and other metabolic inflammatory and fibrotic diseases today announces dosing of the first patient...

Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Chronic Pancreatitis

Wednesday, September 25, 2019

Theraly Fibrosis a preclinicalstage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced that the US Food and Drug Administration has granted Orphan Drug Designation ODD to TLY for...

Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

Wednesday, September 25, 2019

Aldeyra Therapeutics Inctoday announced that the US Food and Drug Administration FDA has granted fast track designation to ADX for the prevention of proliferative vitreoretinopathy PVR PVR is a serious sightthreatening condition with no approved trea...

Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma

Tuesday, September 24, 2019

Xynomic Pharmaceuticals Holdings Inc a clinical stage USChina oncology drug development company today announced that the US Food and Drug Administration FDA has granted FastTrack designation to Xynomics lead drug candidate abexinostat for use as a si...